Pan-Cancer (N=930) | HB-Cancer (N=1151) | Pan-disease (N=4409) | HB-disease (N=21002) | Control (N=5895) | Total (N=33387) | p value | |
---|---|---|---|---|---|---|---|
Gender | < 0.0011 | ||||||
   Female | 439 (47.2%) | 430 (37.4%) | 2043 (46.3%) | 11186 (53.3%) | 1681 (28.5%) | 15779 (47.3%) | |
   Male | 491 (52.8%) | 721 (62.6%) | 2366 (53.7%) | 9816 (46.7%) | 4214 (71.5%) | 17608 (52.7%) | |
Ethnicity | < 0.0011 | ||||||
   White | 519 (66.6%) | 549 (53.7%) | 2370 (57.6%) | 10396 (51.5%) | 3280 (57.7%) | 17114 (53.9%) | |
   South Asian | 79 (10.1%) | 230 (22.5%) | 874 (21.2%) | 5207 (25.8%) | 942 (16.6%) | 7332 (23.1%) | |
   Black | 98 (12.6%) | 121 (11.8%) | 408 (9.9%) | 2046 (10.1%) | 806 (14.2%) | 3479 (10.9%) | |
   Far/South-east Asian | 4 (0.5%) | 24 (2.3%) | 19 (0.5%) | 234 (1.2%) | 31 (0.5%) | 312 (1.0%) | |
   Arab/North African | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) | 15 (0.1%) | 5 (0.1%) | 21 (0.1%) | |
   Asian (Other) | 17 (2.2%) | 46 (4.5%) | 178 (4.3%) | 970 (4.8%) | 234 (4.1%) | 1445 (4.5%) | |
   Mixed | 9 (1.2%) | 8 (0.8%) | 49 (1.2%) | 241 (1.2%) | 78 (1.4%) | 385 (1.2%) | |
   Other | 53 (6.8%) | 45 (4.4%) | 217 (5.3%) | 1065 (5.3%) | 306 (5.4%) | 1686 (5.3%) | |
Diagnosis age (years) | < 0.0012 | ||||||
   Mean (SD) | 66.91 (12.72) | 65.24 (13.22) | 52.90 (18.51) | 53.64 (17.67) | 54.77 (17.59) | 54.51 (17.77) | |
   Median | 67.21 | 66.06 | 51.28 | 52.42 | 54.09 | 53.62 | |
   Q1,Q3 | 58.88, 76.07 | 56.79, 75.15 | 38.36, 67.20 | 39.90, 66.40 | 41.02, 68.00 | 40.66, 67.85 | |
Diagnosis age group | < 0.0011 | ||||||
   18-40 | 27 (2.9%) | 54 (4.7%) | 1318 (29.9%) | 5663 (27.0%) | 1470 (24.9%) | 8532 (25.6%) | |
   41-50 | 66 (7.1%) | 100 (8.7%) | 862 (19.6%) | 4149 (19.8%) | 1097 (18.6%) | 6274 (18.8%) | |
   51-60 | 189 (20.3%) | 266 (23.1%) | 773 (17.5%) | 4186 (19.9%) | 1163 (19.7%) | 6577 (19.7%) | |
   61-70 | 290 (31.2%) | 325 (28.2%) | 574 (13.0%) | 3022 (14.4%) | 961 (16.3%) | 5172 (15.5%) | |
   71-80 | 234 (25.2%) | 273 (23.7%) | 519 (11.8%) | 2311 (11.0%) | 733 (12.4%) | 4070 (12.2%) | |
   >80 | 124 (13.3%) | 133 (11.6%) | 363 (8.2%) | 1671 (8.0%) | 471 (8.0%) | 2762 (8.3%) | |
Mortality | < 0.0011 | ||||||
   Deceased | 754 (81.1%) | 795 (69.1%) | 840 (19.1%) | 3634 (17.3%) | 614 (10.4%) | 6637 (19.9%) | |
   Survived | 176 (18.9%) | 356 (30.9%) | 3569 (80.9%) | 17368 (82.7%) | 5281 (89.6%) | 26750 (80.1%) | |
Survival (months) | < 0.0012 | ||||||
   Mean (SD) | 15.88 (24.91) | 22.37 (29.54) | 49.69 (64.39) | 58.03 (77.33) | 57.50 (71.17) | 54.43 (73.08) | |
   Median | 8.05 | 12.47 | 28.93 | 34.87 | 36.57 | 32.20 | |
   Q1,Q3 | 2.58, 18.18 | 3.52, 29.40 | 9.60, 66.17 | 12.50, 73.46 | 14.57, 71.95 | 11.07, 69.57 |
Pan-Cancer (N=930) | HB-Cancer (N=1151) | Total (N=2081) | p value | |
---|---|---|---|---|
Gender | < 0.0011 | |||
   Female | 439 (47.2%) | 430 (37.4%) | 869 (41.8%) | |
   Male | 491 (52.8%) | 721 (62.6%) | 1212 (58.2%) | |
Ethnicity | < 0.0011 | |||
   White | 519 (66.6%) | 549 (53.7%) | 1068 (59.3%) | |
   South Asian | 79 (10.1%) | 230 (22.5%) | 309 (17.1%) | |
   Black | 98 (12.6%) | 121 (11.8%) | 219 (12.2%) | |
   Far/South-east Asian | 4 (0.5%) | 24 (2.3%) | 28 (1.6%) | |
   Asian (Other) | 17 (2.2%) | 46 (4.5%) | 63 (3.5%) | |
   Mixed | 9 (1.2%) | 8 (0.8%) | 17 (0.9%) | |
   Other | 53 (6.8%) | 45 (4.4%) | 98 (5.4%) | |
Diagnosis age (years) | 0.0092 | |||
   Mean (SD) | 66.91 (12.72) | 65.24 (13.22) | 65.98 (13.03) | |
   Median | 67.21 | 66.06 | 66.73 | |
   Q1,Q3 | 58.88, 76.07 | 56.79, 75.15 | 57.68, 75.68 | |
Diagnosis age group | 0.0521 | |||
   18-40 | 27 (2.9%) | 54 (4.7%) | 81 (3.9%) | |
   41-50 | 66 (7.1%) | 100 (8.7%) | 166 (8.0%) | |
   51-60 | 189 (20.3%) | 266 (23.1%) | 455 (21.9%) | |
   61-70 | 290 (31.2%) | 325 (28.2%) | 615 (29.6%) | |
   71-80 | 234 (25.2%) | 273 (23.7%) | 507 (24.4%) | |
   >80 | 124 (13.3%) | 133 (11.6%) | 257 (12.3%) | |
Mortality | < 0.0011 | |||
   Deceased | 754 (81.1%) | 795 (69.1%) | 1549 (74.4%) | |
   Survived | 176 (18.9%) | 356 (30.9%) | 532 (25.6%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 15.88 (24.91) | 22.37 (29.54) | 19.47 (27.75) | |
   Median | 8.05 | 12.47 | 10.13 | |
   Q1,Q3 | 2.58, 18.18 | 3.52, 29.40 | 2.90, 24.50 |
Pan-Cancer (N=930) | HB-Cancer (N=1151) | Total (N=2081) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 3.43 (2.44) | 3.84 (2.41) | 3.65 (2.43) | |
   Median | 3.00 | 4.00 | 3.00 | |
   Q1,Q3 | 1.00, 5.00 | 2.00, 6.00 | 2.00, 5.00 | |
Diabetes | 353 (38.0%) | 427 (37.1%) | 780 (37.5%) | 0.6872 |
Hypertension | 490 (52.7%) | 698 (60.6%) | 1188 (57.1%) | < 0.0012 |
Cholesterol | 423 (45.5%) | 533 (46.3%) | 956 (45.9%) | 0.7082 |
Asthma | 104 (11.2%) | 133 (11.6%) | 237 (11.4%) | 0.7902 |
COPD | 72 (7.7%) | 87 (7.6%) | 159 (7.6%) | 0.8762 |
TB | 8 (0.9%) | 19 (1.7%) | 27 (1.3%) | 0.1132 |
Kidney | 160 (17.2%) | 226 (19.6%) | 386 (18.5%) | 0.1562 |
Cardiovascular | 262 (28.2%) | 333 (28.9%) | 595 (28.6%) | 0.7032 |
Pancreas | 292 (31.4%) | 134 (11.6%) | 426 (20.5%) | < 0.0012 |
Liver | 99 (10.6%) | 452 (39.3%) | 551 (26.5%) | < 0.0012 |
Biliary | 256 (27.5%) | 380 (33.0%) | 636 (30.6%) | 0.0072 |
Upper GI | 292 (31.4%) | 436 (37.9%) | 728 (35.0%) | 0.0022 |
Lower GI | 109 (11.7%) | 129 (11.2%) | 238 (11.4%) | 0.7152 |
F/H: Cancer | 81 (8.7%) | 154 (13.4%) | 235 (11.3%) | < 0.0012 |
F/H: Digestive | 43 (4.6%) | 41 (3.6%) | 84 (4.0%) | 0.2212 |
F/H: Diabetes | 146 (15.7%) | 234 (20.3%) | 380 (18.3%) | 0.0072 |
Pan-Cancer (N=930) | HB-Cancer (N=1151) | Total (N=2081) | p value | |
---|---|---|---|---|
Smoker | < 0.0011 | |||
   Not available | 289 (31.1%) | 246 (21.4%) | 535 (25.7%) | |
   Never | 238 (25.6%) | 362 (31.5%) | 600 (28.8%) | |
   Past | 236 (25.4%) | 322 (28.0%) | 558 (26.8%) | |
   Current | 167 (18.0%) | 221 (19.2%) | 388 (18.6%) | |
Drinker | < 0.0011 | |||
   Not available | 423 (45.5%) | 407 (35.4%) | 830 (39.9%) | |
   Never | 118 (12.7%) | 217 (18.9%) | 335 (16.1%) | |
   Past | 48 (5.2%) | 75 (6.5%) | 123 (5.9%) | |
   Current | 341 (36.7%) | 452 (39.3%) | 793 (38.1%) | |
Substance user | < 0.0011 | |||
   Not available | 627 (67.4%) | 665 (57.8%) | 1292 (62.1%) | |
   Never | 115 (12.4%) | 189 (16.4%) | 304 (14.6%) | |
   Past | 4 (0.4%) | 11 (1.0%) | 15 (0.7%) | |
   Current | 184 (19.8%) | 286 (24.8%) | 470 (22.6%) | |
Obese | < 0.0011 | |||
   Not available | 256 (27.5%) | 218 (18.9%) | 474 (22.8%) | |
   Never | 190 (20.4%) | 211 (18.3%) | 401 (19.3%) | |
   Past | 337 (36.2%) | 478 (41.5%) | 815 (39.2%) | |
   Current | 147 (15.8%) | 244 (21.2%) | 391 (18.8%) |
Pan-Cancer (N=540) | HB-Cancer (N=828) | Total (N=1368) | p value | |
---|---|---|---|---|
Gender | < 0.0011 | |||
   Female | 265 (49.1%) | 305 (36.8%) | 570 (41.7%) | |
   Male | 275 (50.9%) | 523 (63.2%) | 798 (58.3%) | |
Ethnicity | < 0.0011 | |||
   White | 324 (60.3%) | 405 (49.5%) | 729 (53.8%) | |
   South Asian | 71 (13.2%) | 210 (25.7%) | 281 (20.7%) | |
   Black | 87 (16.2%) | 107 (13.1%) | 194 (14.3%) | |
   Far/South-east Asian | 2 (0.4%) | 23 (2.8%) | 25 (1.8%) | |
   Asian (Other) | 15 (2.8%) | 37 (4.5%) | 52 (3.8%) | |
   Mixed | 5 (0.9%) | 7 (0.9%) | 12 (0.9%) | |
   Other | 33 (6.1%) | 29 (3.5%) | 62 (4.6%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 67.15 (13.68) | 64.49 (13.64) | 65.54 (13.71) | |
   Median | 67.01 | 65.05 | 65.80 | |
   Q1,Q3 | 57.95, 77.72 | 55.28, 74.80 | 56.50, 75.96 | |
Diagnosis age group | 0.0211 | |||
   18-40 | 19 (3.5%) | 45 (5.4%) | 64 (4.7%) | |
   41-50 | 41 (7.6%) | 77 (9.3%) | 118 (8.6%) | |
   51-60 | 115 (21.3%) | 210 (25.4%) | 325 (23.8%) | |
   61-70 | 148 (27.4%) | 222 (26.8%) | 370 (27.0%) | |
   71-80 | 124 (23.0%) | 176 (21.3%) | 300 (21.9%) | |
   >80 | 93 (17.2%) | 98 (11.8%) | 191 (14.0%) | |
Mortality | < 0.0011 | |||
   Deceased | 437 (80.9%) | 545 (65.8%) | 982 (71.8%) | |
   Survived | 103 (19.1%) | 283 (34.2%) | 386 (28.2%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 17.83 (29.58) | 24.85 (32.28) | 22.08 (31.42) | |
   Median | 7.93 | 14.40 | 11.35 | |
   Q1,Q3 | 2.58, 18.38 | 4.35, 33.26 | 3.23, 28.18 |
Pan-Cancer (N=540) | HB-Cancer (N=828) | Total (N=1368) | p value | |
---|---|---|---|---|
Comorbidity | 0.8011 | |||
   Mean (SD) | 4.56 (2.29) | 4.53 (2.32) | 4.54 (2.30) | |
   Median | 4.00 | 4.00 | 4.00 | |
   Q1,Q3 | 3.00, 6.00 | 3.00, 6.00 | 3.00, 6.00 | |
Diabetes | 250 (46.3%) | 345 (41.7%) | 595 (43.5%) | 0.0912 |
Hypertension | 353 (65.4%) | 572 (69.1%) | 925 (67.6%) | 0.1522 |
Cholesterol | 361 (66.9%) | 478 (57.7%) | 839 (61.3%) | < 0.0012 |
Asthma | 78 (14.4%) | 116 (14.0%) | 194 (14.2%) | 0.8222 |
COPD | 52 (9.6%) | 72 (8.7%) | 124 (9.1%) | 0.5562 |
TB | 8 (1.5%) | 18 (2.2%) | 26 (1.9%) | 0.3592 |
Kidney | 133 (24.6%) | 186 (22.5%) | 319 (23.3%) | 0.3542 |
Cardiovascular | 192 (35.6%) | 275 (33.2%) | 467 (34.1%) | 0.3722 |
Pancreas | 165 (30.6%) | 76 (9.2%) | 241 (17.6%) | < 0.0012 |
Liver | 83 (15.4%) | 379 (45.8%) | 462 (33.8%) | < 0.0012 |
Biliary | 186 (34.4%) | 279 (33.7%) | 465 (34.0%) | 0.7752 |
Upper GI | 248 (45.9%) | 410 (49.5%) | 658 (48.1%) | 0.1942 |
Lower GI | 98 (18.1%) | 121 (14.6%) | 219 (16.0%) | 0.0812 |
F/H: Cancer | 81 (15.0%) | 154 (18.6%) | 235 (17.2%) | 0.0852 |
F/H: Digestive | 29 (5.4%) | 38 (4.6%) | 67 (4.9%) | 0.5132 |
F/H: Diabetes | 146 (27.0%) | 234 (28.3%) | 380 (27.8%) | 0.6212 |
Pan-Cancer (N=540) | HB-Cancer (N=828) | Total (N=1368) | p value | |
---|---|---|---|---|
Smoker | 0.7621 | |||
   Not available | 5 (0.9%) | 6 (0.7%) | 11 (0.8%) | |
   Never | 201 (37.2%) | 331 (40.0%) | 532 (38.9%) | |
   Past | 203 (37.6%) | 297 (35.9%) | 500 (36.5%) | |
   Current | 131 (24.3%) | 194 (23.4%) | 325 (23.8%) | |
Drinker | 0.0211 | |||
   Not available | 96 (17.8%) | 154 (18.6%) | 250 (18.3%) | |
   Never | 86 (15.9%) | 183 (22.1%) | 269 (19.7%) | |
   Past | 47 (8.7%) | 74 (8.9%) | 121 (8.8%) | |
   Current | 311 (57.6%) | 417 (50.4%) | 728 (53.2%) | |
Substance user | 0.0241 | |||
   Not available | 331 (61.3%) | 444 (53.6%) | 775 (56.7%) | |
   Never | 72 (13.3%) | 148 (17.9%) | 220 (16.1%) | |
   Past | 4 (0.7%) | 11 (1.3%) | 15 (1.1%) | |
   Current | 133 (24.6%) | 225 (27.2%) | 358 (26.2%) | |
Obese | 0.2371 | |||
   Not available | 7 (1.3%) | 21 (2.5%) | 28 (2.0%) | |
   Never | 117 (21.7%) | 166 (20.0%) | 283 (20.7%) | |
   Past | 292 (54.1%) | 428 (51.7%) | 720 (52.6%) | |
   Current | 124 (23.0%) | 213 (25.7%) | 337 (24.6%) |